42 results about "Nephron" patented technology

The present invention relates to bioartificial devices and systems that mimic kidney or nephron function and methods of making them.

The present invention relates to a method for treating the kidney with extracorporeal shockwaves in a noninvasive manner and in particular, to such a method for the treatment of the nephrons about the glomerulus.

Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs.

Embodiments of the invention relate generally to methods of identifying subjects likely to develop diabetes-associated damage to the nephron, or subjects in the early stages of diabetic nephropathy. In particular, several embodiments relate to quantification of diabetic nephropathy-associated RNA isolated from vesicles from patient urine samples is performed to compare a subject to a population having normal nephron function and / or to track progression of diabetic nephropathy in said subject over time.

Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs.

There is no specific cure for chronic kidney disease (CKD), which affects one in every ten adults. The unmet medical need has created significant interest in regenerative therapeutic approaches. Described herein is a radically new and innovative therapeutic approach identified by characterizing a novel mechanism of renal tissue repair and its role in glomerular injury. By targeting this mechanism in CKD, significant therapeutic benefit supported by rapid cellular remodeling of kidney tissues, coincident with structural and functional nephron regeneration. Methods and compositions for achieving the described therapeutic approach are fundamentally different from existing strategies.

The present invention relates to compositions and methods associated with cocktails of growth factors and small molecules that target specific cell signaling pathways, the cocktails having been formulated to allow / promote the expansion of progenitor cells (e.g., nephron progenitor cells) within a defined culture system.

Provided is a method for producing a nephrosome comprising nephrons, ureteral buds and vasculature and / or progenitor cells of these. In one embodiment, the method comprises contacting mid-mesoderm cells with fibroblast growth factor 9 and / or fibroblast growth factor 20 and / or fibroblasts under conditions that promote the formation of vascularized nephroids Cell growth factor 2, optionally one or more substances selected from the group consisting of: bone morphogenetic protein 7; heparin; Wnt agonist; retinoic acid; and RA antagonist. Another embodiment involves sequentially contacting pluripotent stem cells with a Wnt agonist and fibroblast growth factor 9 and / or fibroblast growth factor 20 and / or fibroblast growth factor 2, followed by a relatively short re-exposure to Wnt agonist to generate mesoderm cells. Nephrosomes may have end uses such as for kidney repair and regeneration, bioprinting of kidneys or their functional components, arrays of kidney cells and screening of compounds for nephrotoxicity.

The invention belongs to the technical field of medical apparatuses and instruments, and provides a self-locking type half kidney loop ligature for a minimally invasive surgery. The self-locking type half kidney loop ligature for the minimally invasive surgery is formed by a kidney ligature (1), a hoop (2), a connecting rod handle (3), a hoop clamping sheet (4), a self-locking pull sheet (5), a self-locking sliding block (6), a sliding block clamping sheet (7) and a movable handle (8). According to the self-locking type half kidney loop ligature for the minimally invasive surgery, by means of controlling the kidney ligature (1), only the blood supply of the kidney of a tumor growth end can be cut off, the effect of tumor removal is guaranteed, blood loss volume in the surgery process is reduced, and most importantly, the ischemia time of reserved parts of the kidney is reduced to zero; the fact that blocking on the blood supply of the whole kidney is avoided, the functions of the reserved parts of the kidney are protected to the maximum extent, and the significance of nephron-sparing surgeries under a peritoneoscope is fully embodied.

The invention relates to a hematodialysis concentrate for improving the residual renal function. The hematodialysis concentrate comprises a hematodialysis concentrate and drugs for promoting blood circulation and removing stasis, and the drugs are ligustrazine, vinpocetine or nimodipine. The hematodialysis concentrate inhibits tubular atrophy and proliferation of fibrous tissues and promotes reversion of disused nephron, improves the blood flow and increases the excretion rate of the renal tubule and the fibrous protein solution, improves blood flow volume of internal arteriovenous fistula, protects the lifeline of a hemodialysis patient, and improves the residual renal function of the residual renal function. The drugs directly permeate to a blood zone from a dialysate zone of a dialyzerin each dialysis treatment and play the roles in preventing platelet aggregation and reducing viscosity of blood in the blood zone, so that a hollow fiber of the dialyzer and a micropore of a dialysismembrane are not easy to block, the effective area for dialysis is kept, the micropore of the dialysis membrane is kept smooth, and the metabolic waste in the blood zone is fully dialyzed and cleared. The hematodialysis concentrate has the functions and effects of expanding arteriole and improving microcirculation and the renal function, and the residual nephron is protected, and the function isimproved.